You can be a partner with us by participating in one of our current research studies.
ADVOCATE: ANCA Associated Vasculitis (AAV) standard therapy includes cyclophosphamide and glucocorticoids (such as Prednisone). Glucocorticoid is the main treatment for this condition; however it comes with significant side effects such as infection. These adverse events highlight the need for other newer medical therapies, as well as new ways to reduce or eliminate the need for chronic (more than a few months) high dose glucocorticoid use in the treatment of patients with AAV. Based on previous encouraging results from other clinical trials, a new therapy called CCX168 (avacopan) has the potential to be used as a treatment for AAV with potential safety and tolerability advantages and has shown to be at least as good as the standard of care regimen that includes high doses of glucocorticoid treatment, such as prednisone. For more information, click here or email firstname.lastname@example.org.
ATHENA: We are recruiting Alport Syndrome Patients to study the natural history of kidney disease progression and current standard of care. For more information, click here or email email@example.com.
PODOCYTE: Focal segmental glomerulosclerosis (FSGS) is a rare disease caused by the scarring of sections of the kidneys (glomeruli). Each kidney is made up of several glomeruli that aid the body in filtering waste products from the blood. This waste is removed from the body in the form of urine. When the glomeruli become scarred, the filtering mechanism does not work correctly and the result is that the kidneys allow an excess amount of protein that is normally found in the blood to escape in the urine (called proteinuria). H.P. Acthar® Gel is a drug approved by the FDA and used to treat patients with proteinuria and this study will examine the effects of this study medication for FSGS. The thought is that by improving proteinuria that it can improve the disease. For more information, click here or email firstname.lastname@example.org
Testing: IgA nephropathy is one of most common reasons for kidney failure, especially in younger adults. Decreased kidney function, high blood pressure and the presence of protein in the urine (proteinuria) are the strongest risk factors for kidney failure. Current therapies include blood pressure control for patients with proteinuria and/or hypertension, but a substantial risk of kidney failure remains even when these therapies are given. This study will evaluate the long-term effectiveness and safety of oral methylprednisolone compared to matching placebo, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression. For more information, click here or email email@example.com.
For more information regarding different types of clinical studies, reasons to participate and what to expect, please visit the PHSA website.